KOSPIBiotech & Pharma000020

Dongwha Pharm

₩4,945▲ 0.71%2026-11-18 close
Market Cap
₩138.1B
Turnover
₩500M
Volume
100K
Shares out.
27.9M
PER
7.7×
PBR
0.3×
EPS
₩644
Dividend Yield
1.31%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩65 per share · Prices as of the 2026-11-18 close

01

Report overview

Dongwha Pharm: OTC-Led Profit Recovery, Durability Is the Test

Dongwha Pharm returned to operating profit in Q1 2026 on cost cuts and OTC sales, but whether the recovery can last after the operating margin fell to 0.1% in 2025 is the central question.

  1. 1

    After an operating loss of KRW 4 billion in Q4 2025, operating profit turned to KRW 11.2 billion in Q1 2026, then declined for two consecutive quarters to KRW 10.3 billion in Q2 and KRW 3.83 billion in Q3 2026.

  2. 2

    Annual operating profit declined for three consecutive years from 2023 to 2025, and 2025 operating profit was KRW 257 million, down 98.1% from the prior year. The company attributed the drop mainly to higher costs from its business restructuring.

  3. 3

    Net profit attributable to controlling shareholders rose 56.1% to KRW 8.69 billion in 2025, while the sum over the last four quarters (Q4 2025 to Q3 2026) was KRW 17.9 billion.

  4. 4

    The debt-to-equity ratio rose from 21.8% in 2022 to 60.0% in 2025, raising the company's reliance on borrowed funds relative to equity.

  5. 5

    Company-produced pharmaceuticals accounted for 60.3% of consolidated revenue in the first half of 2026, while the Vietnamese pharmacy chain TS Care posted a net loss of KRW 3.5 billion in the same period, making the durability of the margin recovery the key issue.

02

Business structure

Dongwha Pharm, founded in 1897 and listed on the main board in 1976, is one of Korea's oldest listed pharmaceutical companies. Its core business is making and selling pharmaceuticals and quasi-drugs, complemented by health functional foods, medical devices and a pharmacy distribution chain.

In the first half of 2026, company-produced pharmaceuticals generated KRW 161.3 billion, or 60.3% of consolidated revenue of KRW 267.5 billion, followed by merchandise sales of KRW 53.5 billion (20%) and Vietnam distribution sales of KRW 35.5 billion (13.3%).

By product, Hwalmyeongsu products were the largest at KRW 42 billion, or 15.7% of revenue, followed by Pancol at KRW 29.6 billion (11.1%), Itchi at KRW 21.6 billion (8.1%) and Husidin at KRW 11.9 billion.

In Q2 2026, other pharmaceutical sales rose 66.1% year on year to KRW 18.9 billion, and exports within that line grew 183.3% to KRW 5.3 billion. The medical device subsidiary posted first-half 2026 revenue of KRW 15.9 billion and net income of KRW 3.7 billion, and the parent raised its stake in it to 62.07%.

In Vietnam, the TS Care pharmacy chain's first-half 2026 revenue fell 14.7% to KRW 35.5 billion and it recorded a net loss of KRW 3.5 billion. Rental income from the new headquarters building added KRW 1.5 billion in revenue and KRW 0.9 billion in operating profit in the first half of 2026.

Hwalmyeongsu-line liquid digestive products remain the market leader, and Husidin ointment, Pancol and Itchi are also reported to hold solid market positions. The newer Curip brand is cited by the company and media as a fast-growing part of the living health business.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩122B₩1.4B1.1%
2025Q4₩123.7B-₩4B−3.2%
2026Q1₩130.6B₩11.2B8.6%
2026Q2₩136.9B₩10.3B7.5%
2026Q3₩129.9B₩3.8B2.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩340.4B₩29.9B₩20.4B8.8%5.6%21.8%
2023₩361.1B₩18.8B₩27.4B5.2%7.4%38.8%
2024₩464.9B₩13.4B₩5.6B2.9%1.5%54.3%
2025₩496.4B₩300M₩8.7B0.1%2.3%60.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 340.4 billion in 2022 to KRW 361.1 billion in 2023 (up 6.1% year on year), KRW 464.9 billion in 2024 (up 28.7%) and KRW 496.4 billion in 2025 (up 6.8%), marking three consecutive years of increases from 2023 to 2025.

Over the same period operating profit went from KRW 29.9 billion in 2022 to KRW 18.8 billion in 2023 (down 37.2%), KRW 13.4 billion in 2024 (down 28.6%) and KRW 257 million in 2025 (down 98.1%), marking three consecutive years of declines from 2023 to 2025.

Revenue grew while profitability moved the other way, with the operating margin falling from 8.8% in 2022 to 5.2% in 2023, 2.9% in 2024 and 0.1% in 2025.

In 2024 the addition of two subsidiaries with roughly KRW 100 billion in annual revenue lifted sales, but the company attributed the sharp 2025 profit drop to higher restructuring costs and one-time expenses amid an economic slowdown.

Net profit attributable to controlling shareholders was KRW 20.4 billion in 2022, KRW 27.4 billion in 2023 (up 34.6%), KRW 5.56 billion in 2024 (down 79.7%) and KRW 8.69 billion in 2025 (up 56.1%), while net income including non-controlling interests was KRW 3.84 billion in 2025.

At the end of 2025, total equity was KRW 401.4 billion, of which KRW 379.5 billion was attributable to controlling shareholders, and the debt-to-equity ratio had risen from 21.8% in 2022 to 60.0%.

Operating cash flow was KRW 29.2 billion in both 2022 and 2023, negative KRW 4 billion in 2024 and KRW 15.7 billion in 2025. Quarterly, operating profit was KRW 1.37 billion in Q3 2025, turned to an operating loss of KRW 4 billion in Q4 2025, and returned to KRW 11.2 billion in Q1 2026.

In Q1 2026 selling and administrative expenses fell 7.7% year on year to KRW 43.2 billion, with advertising and promotion costs down KRW 1.9 billion and KRW 0.9 billion, while financial costs rose 91.3% to KRW 5.3 billion.

Operating profit then fell to KRW 10.3 billion in Q2 and KRW 3.83 billion in Q3 2026, as selling and administrative expenses rose from KRW 42.5 billion in Q2 to KRW 45.7 billion in Q3.

05

Industry analysis

Korea's pharmaceutical sector faces policy uncertainty from revisions to the drug pricing system.

As the government revises pricing rules, price preferences for innovative pharmaceutical companies have grown in weight, and analysts note that the outcome of the innovative company recertification could affect future profitability.

Dongwha Pharm's ability to keep its existing status in the recertification scheduled this year is cited as a key variable. Over-the-counter drugs, unlike prescription drugs, are reported to be less exposed to price cuts, which is why they are seen as a stable source of cash.

Hwalmyeongsu remains the leader in liquid digestive remedies, and Pancol, Itchi and Husidin also hold solid market positions. Cold medicines, digestive remedies and gum and wound treatments are categories whose demand shifts with season and flu trends, which adds to quarterly revenue swings.

The medical device segment is viewed as having high growth potential from the convergence of biotech and IT, and the subsidiary's Q2 2026 revenue rose 14.5% from the prior quarter to about KRW 8.5 billion.

Vietnam's drug distribution is cited for growth potential from a widening middle class and rising health awareness, but ongoing losses at TS Care mean that potential is reaching the income statement slowly.

Other OTC-focused peers are also expanding into beauty, healthcare and medical devices, and Dongwha Pharm is pursuing a similar portfolio expansion. The sector's key questions come down to whether price preferences are maintained and whether the company can defend profitability in its own-brand OTC business.

06

Outlook

In its 2025 results announcement, the company said it expected profitability to improve significantly in 2026, and operating profit stayed positive in each quarter from Q1 to Q3 2026.

On the Q2 2026 results, the company said revenue growth and cost efficiency had a positive effect on operating profit and pledged steady growth through stronger core brands and a broader product portfolio. In Q1 2026, the growth of new brands such as Curip was highlighted.

The parent has reportedly raised its stake in the medical device subsidiary to 62.07% and is also pursuing a KOSDAQ transfer listing for that subsidiary.

In Vietnam, the view is that TS Care must return to normal before the global strategy can gain traction, and in the first half of 2026 the parent added about KRW 6.8 billion to raise its stake in TS Care from 55.99% to 65.00%.

A Korean financial newspaper cited the United States as the next major challenge, but no timing or scale for entry has been confirmed. Rental income from the new headquarters building was added as a revenue source in the first half of 2026.

The next checkpoints are whether Q4 2026 operating profit exceeds the KRW 3.83 billion of Q3, and whether the innovative company recertification preserves price preferences.

07

Valuation

PER
7.7×
PBR
0.3×
ROE
4.6%
EPS
₩644
BPS
₩14,275
Dividend per share
₩65

Valuation is easiest to read along two axes: earnings level and book value.

The sum of net profit attributable to controlling shareholders over the last four quarters (Q4 2025 to Q3 2026) was KRW 17.9 billion, and the quarterly path moved sharply from KRW 10 billion in Q1 2026 to KRW 740 million in Q3, so multiples are highly sensitive to the period used.

On an annual basis, net profit attributable to controlling shareholders fell from KRW 27.4 billion in 2023 to KRW 5.56 billion in 2024 before recovering to KRW 8.69 billion in 2025, which makes it hard to anchor on any historical multiple.

On a book value basis, the stake attributable to controlling shareholders was KRW 379.5 billion at the end of 2025, and market capitalization sits well below that figure, meaning the share price is trading at a steep discount to book.

Total equity of KRW 401.4 billion sits alongside liabilities of KRW 240.7 billion, and the debt-to-equity ratio of 60.0% is higher than the 21.8% recorded in 2022.

Dividend capacity depends on operating cash flow of KRW 15.7 billion in 2025 and the borrowing level, so dividend durability should be read together with those two figures. Because quarterly earnings swing widely, how the multiples are interpreted depends on whether the profit recovery holds.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Q1 turnaround and cost control

Operating profit returned to KRW 11.2 billion in Q1 2026 from an operating loss of KRW 4 billion in Q4 2025. Selling and administrative expenses fell 7.7% year on year to KRW 43.2 billion in the same quarter, with lower advertising and promotion costs accounting for a large part of the gain. First-half 2026 operating profit reached KRW 21.5 billion, up 646.3% from a year earlier.

Own-brand weight and export growth

Own brands such as Hwalmyeongsu, Pancol and Itchi are reported to be less affected by price cuts than prescription drugs. Company-produced pharmaceuticals generated KRW 161.3 billion in the first half of 2026, or 60.3% of consolidated revenue. Exports within other pharmaceutical sales rose 183.3% year on year in Q2 2026, widening overseas channels.

Cash generation and rental income

Operating cash flow in the first half of 2026 reached KRW 19 billion, up 158.3% year on year, and cash and equivalents stood at KRW 22 billion.

Rental income from the new headquarters building generated KRW 1.5 billion in revenue and KRW 0.9 billion in operating profit in the first half, adding cash flow outside the core business. Operating cash flow was back in positive territory at KRW 15.7 billion in 2025.

09

Bear factors

Sharp Q3 profit drop and rising SG&A

Operating profit fell 62.8% from the prior quarter to KRW 3.83 billion in Q3 2026, and net profit attributable to controlling shareholders dropped 88.8% to KRW 740 million. Selling and administrative expenses rose from KRW 42.5 billion in Q2 to KRW 45.7 billion in Q3, weakening the effect of cost control. Year-on-year the quarter still improved, but the quarter-to-quarter trend points the other way.

Continued losses at TS Care in Vietnam

TS Care's first-half 2026 revenue fell 14.7% year on year to KRW 35.5 billion, and it remained loss-making with a net loss of KRW 3.5 billion. In the same period the parent added about KRW 6.8 billion to lift its TS Care stake from 55.99% to 65.00%. If the Vietnam pharmacy business does not normalize, it will weigh on the assessment of the global strategy.

Financial burden and higher financing costs

The debt-to-equity ratio rose from 21.8% in 2022 to 60.0% in 2025, and total liabilities at the end of 2025 were KRW 240.7 billion. Financial costs in Q1 2026 rose 91.3% year on year to KRW 5.3 billion. Total borrowings stood at KRW 107.1 billion at the end of June 2026, up from KRW 102.2 billion at the end of 2025.

10

Risk factors

Policy risk (drug pricing and recertification)

Recertification as an innovative pharmaceutical company is linked to price preferences, so the outcome could affect profitability, particularly in prescription products. If the details of the government's drug pricing revision change, the pricing structure of the company's products could also shift. The recertification outcome and the timing of any price adjustments remain the next points to watch.

Overseas and subsidiary risk

Continuing losses at TS Care add to the cumulative investment burden on the Vietnam business. The 62.07% stake in the medical device subsidiary and the pursuit of a KOSDAQ transfer listing could change consolidated results and the ownership structure. Until overseas expansion plans take concrete form, cost burdens may show up in results first.

Earnings volatility and cost structure

Net profit attributable to controlling shareholders swung from KRW 27.4 billion in 2023 to KRW 5.56 billion in 2024 and back to KRW 8.69 billion in 2025, a wide range. Even with KRW 17.9 billion over the last four quarters, quarter-to-quarter differences are large, making durability hard to judge.

Because the company attributed the 2025 profit drop to one-time costs, whether similar costs recur is a key variable.

11

What to watch next

  1. By end of 2026 (scheduled this year)

    Whether the innovative pharmaceutical company recertification preserves the company's status and its price preferences is the next checkpoint. The outcome could shift pricing and the profitability outlook for prescription products.

  2. Around late January 2027

    The 2026 preliminary annual results will show whether Q4 operating profit exceeds the KRW 3.83 billion of Q3, with the KRW 4 billion operating loss of Q4 2025 as the comparison base.

  3. Late March 2027

    The 2026 annual report will fix full-year results and financial indicators on a DART regular-filing basis, with changes in the 60.0% debt-to-equity ratio and KRW 15.7 billion operating cash flow (2025) to be checked.

  4. Mid-May 2027

    The Q1 2027 quarterly report will show whether operating profit can hold near the KRW 11.2 billion peak of Q1 2026, with the direction of selling and administrative expenses and financing costs also important.

12

Overall view

Dongwha Pharm's earnings can be read in two directions. Operating profit declined for three consecutive years from 2023 to 2025 and the operating margin fell to 0.1%, but in 2026 the company returned to a KRW 11.2 billion operating profit in Q1 and KRW 21.5 billion for the first half, signaling a recovery.

The recovery rests mainly on sustained sales of core OTC products and cuts to selling, advertising and promotion costs, as both company statements and media coverage indicate.

However, operating profit declined in Q2 and Q3 2026 and Q3 selling and administrative expenses rose again, so the durability of cost control needs further confirmation.

The losses at TS Care in Vietnam, higher financial costs in Q1 2026 and the rise in the debt-to-equity ratio to 60.0% are weaknesses that could offset the margin recovery.

On the other hand, a high share of own brands and operating cash flow back in positive territory at KRW 15.7 billion in 2025 are strengths in the financial base.

Viewed against net profit attributable to controlling shareholders of KRW 17.9 billion over the last four quarters and a stake attributable to controlling shareholders of KRW 379.5 billion, the valuation picture shows both earnings volatility and a gap with book value.

The next checkpoints are the 2026 preliminary annual results, the 2026 annual report and the outcome of the innovative company recertification. This report includes no investment opinion, rating or target price, and its figures are based on DART regular filings and public disclosures and reporting.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kr.investing.com
  2. ebn.co.kr
  3. m.yakup.com
  4. thebionews.net
  5. newstong.co.kr
  6. dealsite.co.kr
  7. dealsite.co.kr
  8. dealsite.co.kr
  9. m.news.nate.com
  10. dealsite.co.kr
  11. vegannews.co.kr
  12. dailypharm.com
  13. comp.wisereport.co.kr
  14. asiatoday.co.kr
  15. dailypharm.com
  16. m.news.nate.com
  17. m.news.nate.com
  18. fntimes.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis